Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 151 clinical trials
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined by the

  • 10 views
  • 21 Jan, 2021
  • 38 locations
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients 60 Years in Deep Molecular Response

(Tasigna), or Dasatinib (Sprycel) will be given intermittently at the same daily dose that was given daily at the time of the enrollment . Chronic phase Ph+ CML patients in stable major molecular response

kinase inhibitor
nilotinib
dasatinib
gleevec
imatinib
  • 3 views
  • 31 Jul, 2021
  • 1 location
DC Vaccination in CML

residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML (chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission. These patients can be included

residual tumor
tyrosine
leukemia
bcr-abl protein
remission
  • 6 views
  • 16 Aug, 2021
  • 2 locations
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

This study will be a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the

  • 0 views
  • 18 Aug, 2021
  • 5 locations
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

imatinib (Glivec®) in pretreated Philadelphia chromosome- positive (Ph+)/BCR-ABL+ CML patients in chronic phase.

interferon
leukemia
philadelphia chromosome
gleevec
imatinib
  • 11 views
  • 07 Nov, 2020
  • 1 location
Treatment Modification Based on Early Assessment of CML Patients

The investigators will check the feasibility of using early molecular response for making treatment decisions. Patients diagnosed with chronic myeloid leukemia will commence imatinib treatment

leukemia
philadelphia chromosome
imatinib
tyrosine
philadelphia chromosome positive chronic myelogenous leukemia
  • 5 views
  • 08 Nov, 2020
  • 1 location
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia

  • 38 views
  • 11 May, 2021
  • 442 locations
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia

The treatment of CML and the expected survival has been revolutionised since the introduction of tyrosine kinase inhibitors (TKIs) such as nilotinib. Despite their effectiveness, these drugs

leukemia
basophils
hydroxyurea
anagrelide
lipase
  • 10 views
  • 07 Nov, 2020
  • 1 location
Dasatinib Holiday for Improved Tolerability

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment nave disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase

ponatinib
leukemia
hydroxyurea
imatinib
dasatinib
  • 11 views
  • 05 Feb, 2021
  • 80 locations
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy

imatinib
remission
leukemia
interferon
  • 8 views
  • 07 Nov, 2020
  • 1 location